

14 December 2021

OMEGA DIAGNOSTICS GROUP PLC ("Omega" or the "Company" or the "Group")

Confirmation of detection of Omicron variant

VISITECT® COVID-19 antigen test performs with the same high accuracy on the Omicron variant

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, has been notified by its technology partner Mologic Ltd ("Mologic") that data from analysis on clinical samples, as well as in-silico analysis, show that the Mologic Covios® Ag lateral flow test, performs with the same high accuracy on the Omicron variant as it does with existing known variants.

This is the same test that is manufactured and sold for professional use by Omega as the VISITECT® COVID-19 antigen test.

Colin King, CEO, Omega Diagnostics, said: "We are very pleased be in a position to confirm that the VISITECT® COVID-19 antigen test is able to equally detect the Omicron variant, as well as other existing variants. We remain encouraged by emerging commercial opportunities for our VISITECT® COVID-19 Antigen test that we expect to be unlocked following relevant approval under CTDA regulations and CE-marking for home-use."

Contacts:

Omega Diagnostics Group PLCwww.omegadx.comColin King, Chief Executive Officervia Walbrook PRChris Lea, Chief Financial Officer

finnCap Ltd Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)
Alice Lane/ Charlotte Sutcliffe (ECM)

Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com

 Paul McManus
 Mob: 07980 541 893

 Lianne Applegarth
 Mob: 07584 391 303

 Sam Allen
 Mob: 07502 558 258

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health. www.omegadx.com